MedTrace Logo

First-line Treatment of Advanced/unresectable DDLPS

NCT06694324 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2024-11-19

No results posted yet for this study

Summary

Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma

Conditions

  • Dedifferentiated Liposarcoma
  • Soft Tissue Sarcoma (STS)

Interventions

DRUG

Liposomal Doxorubicin (Doxil)

30 mg/m2, d1, IV

DRUG

Apatinib

250 mg, qd

DRUG

Camrelizumab

200 mg, d1, IV

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Zhiguo Luo, MD, PhD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2026-06-01
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06694324 on ClinicalTrials.gov